Molecular Partners to present updates on DLL3-targeting Radio-DARPin MP0712 at major cancer conferences.

Molecular Partners, a clinical-stage biotech company, announced it will present data on its lead Radio-DARPin candidate MP0712, designed for targeted radiotherapy against DLL3 in small cell lung cancer, at several upcoming scientific conferences. These presentations will cover molecular characteristics, preclinical insights, and first human trial data, highlighting progress in developing novel cancer therapies. This exposure at key events may advance clinical development and partnerships for MP0712 and related therapeutics.